Kidswell Bio (4584) · TargetRaised
Creation of the world's first regenerative medicine product using SHED
First written in FY2023-Q3. 1 of 3 entries say "Restated". Latest entry: FY2024-Q3.
3entries
2years
0from disclosures
How it moved
Same theme, other companies
Creation of the world's first SHED cell and gene therapy productsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2024-Q3RaisedAnnual report
「The newly established company aims to create the world's first SHED cell and gene therapy products and other products based on the stable supply platform for stem cells from human exfoliated deciduous teeth (SHED), “S-Quatre®: SHED Source Supply Service” (hereinafter, “S-Quatre®”).」
The scope of the goal has been expanded from “regenerative medicine products derived from SHED” to the creation of the world's first SHED cell and gene therapy products and other products based on S-Quatre. - FY2024-Q1RestatedAnnual report
「The Company aims to commercialize the world's first regenerative medicine product derived from stem cells from human exfoliated deciduous teeth (SHED).」
The Company has reconfirmed its goal of commercializing SHED as the world's first regenerative medicine product. - FY2023-Q3First statedAnnual report
「The Company intends to create the world's first regenerative medicine product using SHED, a growth driver for the Company.」
The Company has positioned SHED as a growth driver and set the creation of the world's first regenerative medicine product using SHED as a new explicit goal.